About this document

Finerenone by Mayi Gf is a document available to read on EtoBox.

The document summarizes the rationale and design of the FIDELIO-DKD trial, which evaluated the effect of the novel mineralocorticoid receptor antagonist finerenone on chronic kidney disease outcomes in patients with type 2 diabetes. The trial aimed to address the high residual risk of kidney disease progression with current therapies by targeting inflammation and fibrosis through mineralocorticoid receptor antagonism. It enrolled patients with diabetic kidney disease stage G1-G4 and albuminuria categories A

Author

Mayi Gf

Language

EN